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Department of Physiology, Anatomy and Genetics, University of Oxford, OX1 3PT, UKSickle Cell Disease (SCD) is one of the most common severe normal individuals. This feature causes solute loss and shrinkage, in-
inherited disorders. Approximately 300,000 SCD babies are born yearly,
mostly in Africa, theUSA and the Caribbean, but also inNorthern Europe
(Piel et al., 2013). In the UK, SCD patients number around 12–15,000
individuals (Hickman et al., 1999) making it a disease of considerable
signiﬁcance. There is no speciﬁc treatment. Nor is it understood why
some patients have amore severe course of the disease, whereas others
are mildly or even subclinically affected. Without this prognostic
knowledge, it is not possible to instigate more aggressive therapies for
children who will be most compromised later in life. For example,
hydroxyurea therapy for these individuals may lessen later complica-
tions such as renal pathology and stroke.
All SCD patients have the abnormal adult haemoglobin HbS in their
red cells. All the complications of SCD follow from this. HbS has a
substituted amino acid at the 6th codon of the beta chain with valine
replacing glutamic acid. Homozygous SCD patients (HbSS) have two
copies of this altered Hb. Heterozygous HbSC individuals have a second
mutated Hb in addition, HbC in which glutamic acid at the same
position is replaced with lysine.
About two thirds of SCD patients are homozygous HbSS individuals
but patients heterozygous for HbS and HbC (HbSC) constitute about a
third of SCD cases (here termed HbSC disease), making this the second
most common form of SCD (Nagel and Lawrence, 1991 & Nagel and
Platt, 2001; Rees et al., 2010) and therefore representing a clinical prob-
lem of considerable impact. Although HbSC disease is common it is
neglected compared to other haemoglobinopathies, such as sickle cell
anaemia (HbSS) and the thalassaemias. Relatively few studies are con-
ducted on HbSC disease, and most physiological and clinical features
are inferred from studies of homozygous sickle cell anaemia (HbSS).
There is considerable evidence that the two conditions are very
different. Generally HbSC is less severe than HbSS, but still results in
recurrent episodes of pain and progressive organ damage, resulting in
a shortening of life-expectancy by 20–30 years in the northern hemi-
sphere. Some complications are more common in HbSC than HbSS,
most notably proliferative retinopathy leading to visual loss. Laboratory
measurements also demonstrate the difference between the two condi-
tions, with higher haemoglobin and lower rates of haemolysis in HbSC,
and signiﬁcantly lower levels of HbF.
Cation homeostasis of red cells is critical in SCD. Red cells from
patients have elevated cation permeability compared to those fromDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.09.026.
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.creasing intracellular concentration of HbS. This is signiﬁcant because
a small rise in [HbS] will markedly promote sickling in hypoxic areas
of the circulation as the lag time to HbS polymerisation is inversely pro-
portional to a very high [HbS]. Altered cation permeability is an early
event following on from HbS polymerisation and represents an impor-
tant stage in pathogenesis. It is therefore important to understand red
cell cation permeability in SCD.
Hannemann et al., 2015 shows important differences in cation trans-
port comparing HbSC and HbSS patients. They indicate that conductive
pathways represented by the nonspeciﬁc cation conductance (some-
times termed Psickle) and the Ca2+-activated K+ channel (or Gardos
channel) are less active in HbSC compared to HbSS. Also a lower oxygen
tension is required to stimulate these pathways in red cells from HbSC
patients. In contast, the coupled K+ and Cl-transporter, KCl cotransport
(KCC), is increased in HbSC over HbSS. KCC activity varies markedly
between patients and, critically, correlates with disease severity.
These ﬁndings represent an important breakthrough in the study of
SCD in HbSC patients. They immediately suggest two possibilities
whichmay improve patientmanagement. First, identiﬁcation of themo-
lecular and genetic factors regulating the activity of this key transporter
using modern genetic and proteomic methods may increase our under-
standing of the key regulatory features of this transporter. KCC is found
in many tissues. This has potential relevance to various disease states
notably epithelial conditions, and is not limited to SCD. Increased under-
standing of this aspect of HbSC disease will facilitate rational design of
speciﬁc therapies to prevent or ameliorate the deleterious sequelae of
the condition. Second, these studies may also inform the establishment
of biomarkers of severity. It will also allow better prognostication, with
the potential for neonatal DNA testing to identify children who wil
follow a severe clinical course and facilitate early intervention with
disease-modifying treatments.
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